GSK agreed to acquire Rapt Therapeutics for $2.2 billion to add ozureprubart, a long‑acting anti‑IgE monoclonal antibody, to its immunology pipeline. The deal terms call for $58 per Rapt share and closes in Q1 2026. Investors pushed Rapt shares sharply higher on the announcement. Ozureprubart is in a Phase IIb prestIgE program testing prophylactic protection against food allergens with an extended dosing interval (every ~8–12 weeks). Rapt and GSK cite the potential to reach patients ineligible for current anti‑IgE therapy and to reduce dosing burden compared with Xolair (omalizumab). GSK said it plans further development, with pivotal trials expected after Phase IIb readouts; Rapt management framed the acquisition as a route to accelerate global development and commercialization. The acquisition reflects continued large‑cap interest in scaling validated immunology targets via M&A.